# Procedural Workflow — How a Telehealth Bremelanotide Encounter Actually Runs > Step-by-step documentation of a synchronous-video telehealth encounter for bremelanotide: intake, evaluation, validated screeners, informed consent, electronic prescription, fulfillment, and follow-up. Intake, synchronous video visit, validated screening, informed consent, electronic prescription, fulfillment, follow-up — what the procedure actually looks like. ## Step 01 — Intake and medication reconciliation A bremelanotide telehealth encounter typically begins asynchronously, with the patient completing a secure intake form. The form is structured to capture the items the label and the standard of care require: medical and psychiatric history, current medications (with explicit attention to oral naltrexone, monoamine oxidase inhibitors, and antihypertensives), surgical and pregnancy history, blood-pressure history with any home-cuff readings the patient can supply, skin-type and existing pigmentation history, and a structured HSDD screen using the Decreased Sexual Desire Screener (DSDS), the FSFI desire domain, and FSDS-DAO Item 13 [12][15][18]. The intake is not a substitute for the video visit; it is the foundation on which the clinician structures the synchronous evaluation. ## Step 02 — Synchronous video visit with a state-licensed clinician The provider-patient relationship is established by a real-time synchronous audiovisual encounter with a clinician licensed in the state where the patient is physically located at the time of the visit [12][18]. Most state medical boards accept the synchronous video encounter as sufficient to establish the relationship for non-controlled prescribing; specifics vary by state, and clinicians who practice across multiple states typically rely on multi-state licensure or interstate compacts such as the Interstate Medical Licensure Compact to extend their reach. The clinicians who most commonly perform this evaluation are OB/GYNs, sexual medicine specialists affiliated with the International Society for the Study of Women's Sexual Health, family medicine physicians, and internal medicine physicians. The 2025 ACOG Committee Statement No. 20 frames telehealth as ethically appropriate for the OB/GYN scope of practice when licensure, informed consent, documentation, and equity standards are met [18]. The 2020 sexual-medicine telehealth review confirms that the majority of sexual-medicine encounters — including the HSDD evaluation — can be conducted by video visit when documentation and consent standards are preserved [15]. ## Step 03 — Clinical evaluation and validated screening During the synchronous encounter the clinician administers or reviews the validated screeners — DSDS, FSFI desire domain, FSDS-DAO Item 13 — and uses the biopsychosocial framework to establish a clinical diagnosis of acquired, generalized HSDD before considering pharmacotherapy [12]. The biopsychosocial framework screens for biological, psychiatric, medication-related, and relational contributors. The 5th ICSM recommendations describe this stepped evaluation explicitly [12]. The diagnostic threshold matters: the FDA indication is acquired, generalized HSDD in premenopausal women; lifelong or situational presentations and postmenopausal patients are not within the approved indication [06]. The cardiovascular screen is performed in this step. The clinician confirms that the patient does not have uncontrolled hypertension or known cardiovascular disease, and reviews any home blood-pressure readings the patient has provided. Some platforms require a documented blood-pressure reading — taken by the patient with an at-home cuff or by a community pharmacy measurement — before issuing the prescription [05][18]. ## Step 04 — Informed consent Informed consent for bremelanotide is specific. It documents that the patient understands the labeled common adverse events (nausea ~40%, flushing ~20%, headache ~11%, injection-site reactions ~13%) [03], the transient post-dose systolic blood-pressure increase observed in ambulatory monitoring [05], the focal hyperpigmentation risk that is more common with darker skin types and frequent dosing and may not fully resolve [08], the eight-doses-per-month upper limit [06], and the contraindication in uncontrolled hypertension and known cardiovascular disease [06][12]. Consent also documents the telehealth modality itself — the patient's understanding that the encounter is delivered remotely, the limits of remote care, and the continuity-of-care expectations [18]. The documentation expectation for telehealth informed consent mirrors the in-person expectation [18]. ACOG Committee Statement No. 20 (2025) is explicit on this point: telehealth providers retain the same continuity-of-care obligations as in-person clinicians [18]. ## Step 05 — Electronic prescription and pharmacy fulfillment The electronic prescription is transmitted to a licensed dispensing pharmacy that ships the FDA-approved bremelanotide product directly to the patient. The product is the single-dose 1.75 mg subcutaneous autoinjector specified by the label [06][10]. The pharmacy that dispenses must be licensed in the state where the patient receives the shipment, and the prescribing clinician must be licensed in the state where the patient was located at the time of the encounter [12][18]. A distinct, separate pathway is the compounded-bremelanotide route. The FDA-approved product and a compounded preparation are not the same regulatory entity: the approved product has been evaluated for identity, purity, stability, and potency under FDA oversight; compounded preparations have not [19]. The FDA has placed PT-141 in its compounding-category framework, restricting eligibility for compounding under certain conditions [19]. The data summarized in this manual applies to the FDA-approved 1.75 mg subcutaneous product. ## Step 06 — Follow-up and continuity of care Follow-up at four to eight weeks — by video visit or secure messaging — is the standard documented in the sexual-medicine telehealth literature [15][18]. The follow-up reviews efficacy (re-administered FSFI-D and FSDS-DAO Item 13), tolerability (nausea, flushing, headache, injection-site experience, hyperpigmentation surveillance), the patient's adherence to the labeled use limits (no more than once per 24 hours; no more than eight doses per month [06]), and any new medications that might have been added since the initial evaluation (with particular attention to oral naltrexone [07]). The clinician documents a continuity-of-care plan — either ongoing telehealth follow-up with the same clinician or platform, or transition back to an in-person clinician — as required by the standard of care for the patient's state and by ACOG's 2025 framing [18]. ## Signals of a legitimate vs. questionable platform Not every site that markets 'PT-141 online' performs this workflow. A legitimate telehealth pathway has a synchronous video encounter with a state-licensed clinician who can be named and credentialed; validated screening (DSDS, FSFI, FSDS-DAO); a documented blood-pressure review; an informed-consent step specific to bremelanotide; an electronic prescription to a licensed dispensing pharmacy; and a documented follow-up plan. A questionable pathway substitutes a form-and-credit-card flow for the synchronous evaluation, fails to establish a state-licensed provider-patient relationship, or dispenses unverified preparations marketed as 'PT-141' that are not the FDA-approved product [15][18][19]. This distinction matters because the 'telehealth' label has been adopted by both kinds of operations. The sexual-medicine telemedicine literature is clear about the elements that make a remote encounter clinically and legally legitimate [15][18]; the FDA's compounding-category framework is the regulatory counterpart on the dispensing side [19]. --- An independent editorial digest of peer-reviewed literature and regulatory documents on the bremelanotide telehealth pathway — not a clinic, not a pharmacy, not medical advice.